Skip to main content
Figure 2 | Cardiovascular Diabetology

Figure 2

From: Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study

Figure 2

Fasting and postprandial FMD at baseline and 12 weeks after treatment in the control, acarbose and nateglinide groups. At baseline before treatment, fasting FMD was similar among the 3 groups. Postprandial FMD (120 min after cookie load) was significantly lower than fasting FMD in each group. After 12 weeks of treatment, fasting FMD was not significantly different in any of the 3 groups compared to baseline before treatment. Postprandial FMD was lower than fasting FMD in all 3 groups. Postprandial FMD was significantly higher in the acarbose group than in the control group after 12 weeks of treatment.

Back to article page